Novo’s $165m REPAIR fund seeks to support projects from LO to Phase 1

Dear All:

Just announced today (press releasewebsite), Novo Holdings has created a $165m impact fund that seeks to support novel therapies from Lead Optimization (LO) through Phase 1. The fund specifically targets “first-in-class therapies, covering small molecules, biologics, and new modalities.” Similar to the focus of CARB-X, REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) will focus on priority pathogens from the CDC and WHO priority lists. 

The origin of the idea for this project appears to be from social impact goals of the Novo Nordisk Foundation: “The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people. The Foundation donates about $300-600 million per year primarily for medical research.”

A first round of investments dedicated to European companies will start in April 2018 (non-confidential presentations can be sent until 15 May 2018) and is expected to lead to investments by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018.

All told, the fund expects to invest USD 20-40 million per year over 3–5 years in about 20 projects in Europe and the United States. The overall goal is at least one new therapy reaching the market.

It’s exciting to see this additional source of push funding! Although funds from REPAIR are presumably dilutive in nature (rather than the non-dilutive financing of CARB-X), the availability of funds from a group who understand the challenge and opportunity of antimicrobial resistance will be a powerful new force for progress. Thank you, Team Novo!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future:

Upcoming meetings of interest to the AMR community:


WHO Bacterial Priority Pathogen List (PPL): 2024 update

Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs., the AMR.Solutions webpage

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

New UK 5-year AMR plan: Subscription model details!

Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are

ESCMID’s UNGA 2024 Petition to EU Health Ministers: Sign and Send!

Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the

Scroll to Top